FORA Capital LLC Invests $272,000 in Progyny, Inc. (NASDAQ:PGNY)

FORA Capital LLC purchased a new position in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 15,758 shares of the company's stock, valued at approximately $272,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Signaturefd LLC boosted its holdings in Progyny by 1,355.0% in the 4th quarter. Signaturefd LLC now owns 1,455 shares of the company's stock valued at $25,000 after purchasing an additional 1,355 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Progyny by 341.4% in the 4th quarter. GAMMA Investing LLC now owns 1,611 shares of the company's stock valued at $28,000 after purchasing an additional 1,246 shares in the last quarter. Nisa Investment Advisors LLC boosted its holdings in Progyny by 108.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company's stock valued at $51,000 after purchasing an additional 1,526 shares in the last quarter. Caitlin John LLC boosted its holdings in Progyny by 2,974.8% in the 4th quarter. Caitlin John LLC now owns 3,290 shares of the company's stock valued at $57,000 after purchasing an additional 3,183 shares in the last quarter. Finally, Natixis purchased a new stake in Progyny in the 4th quarter valued at approximately $69,000. Hedge funds and other institutional investors own 94.93% of the company's stock.

Progyny Stock Up 3.3%

Shares of Progyny stock traded up $0.72 during trading on Friday, hitting $22.67. 430,522 shares of the company were exchanged, compared to its average volume of 1,709,044. Progyny, Inc. has a fifty-two week low of $13.39 and a fifty-two week high of $30.42. The stock has a market capitalization of $1.94 billion, a price-to-earnings ratio of 39.05, a P/E/G ratio of 2.39 and a beta of 1.37. The firm has a 50 day moving average price of $22.03 and a 200 day moving average price of $19.68.

Progyny (NASDAQ:PGNY - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.45 by ($0.28). The firm had revenue of $324.04 million for the quarter, compared to analyst estimates of $307.86 million. Progyny had a return on equity of 11.36% and a net margin of 5.03%. The company's quarterly revenue was up 16.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.17 earnings per share. Analysts predict that Progyny, Inc. will post 0.6 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on PGNY. Bank of America lifted their price objective on Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a report on Tuesday, February 11th. BTIG Research raised Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price target on the stock in a research note on Monday, March 31st. JPMorgan Chase & Co. boosted their price target on Progyny from $17.00 to $23.00 and gave the stock a "neutral" rating in a research note on Tuesday, January 28th. Finally, Canaccord Genuity Group decreased their price target on Progyny from $23.00 to $21.00 and set a "hold" rating on the stock in a research note on Monday. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $23.45.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.